Regeneron Pharmaceuticals Inc (REGN) stock news · P/E 20, rev $14.34B
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
This REGN news page leads with what Regeneron Pharmaceuticals Inc filed — not a scraped headline mill.
No cached 8-K sentence for REGN yet. We will not pad this page with generic market recap.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 19.7.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the REGN stock page; for the tape open the quote page.
REGN stock news FAQ
What are REGN's latest revenue and net income?
Latest cached Regeneron Pharmaceuticals Inc (REGN) revenue for Dec 31, 2025 was $14.34B. Net income was $4.50B. Statements: https://lician.com/financials/regn
How did REGN revenue change from the prior cached period?
Cached Regeneron Pharmaceuticals Inc (REGN) revenue was up 1.0% from $14.20B (Dec 31, 2024) to $14.34B (Dec 31, 2025). Statements: https://lician.com/financials/regn
What is REGN's P/E ratio?
Regeneron Pharmaceuticals Inc (REGN) trailing P/E is 19.7 on the latest cached fundamentals snapshot.
What is REGN's market cap?
Regeneron Pharmaceuticals Inc (REGN) market cap is $59.10B on the latest cached fundamentals snapshot.
What kind of company is REGN?
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Where is REGN stock news listed?
Cached stock news for Regeneron Pharmaceuticals Inc (REGN) is listed at https://lician.com/news/regn. Filings: https://lician.com/sec/regn
Not investment advice.